Cases & Deals

Infinity Pharmaceuticals develops global patent portfolio for IPI-549

Clients Infinity Pharmaceuticals Inc.

Jones Day represents Infinity Pharmaceuticals, Inc. in the establishment of a global patent portfolio related to IPI-549, a small molecule selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma) for the treatment of cancer.